More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Progranulin (human) ELISA Kit

Progranulin (human) ELISA Kit

Research Use Only
AG-45A-0018YTP
AdipoGen Life Sciences
DownloadMSDS
Product group Assays
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Progranulin (human) ELISA Kit
  • Delivery Days Customer
    10
  • Applications
    ELISA
  • Assay Detection Range
    0.063 to 4ng/ml
  • Assay Sensitivity
    32pg/ml
  • Assay Specificity
    Detects human progranulin.
  • Certification
    Research Use Only
  • Scientific Description
    ELISA Assay. Detects human progranulin. Colorimetric assay. Sample Types: Cell Culture Supernatant, Plasma, Serum, Urine. Range: 0.063 to 4ng/ml. Sensitivity: 32pg/ml. Progranulin (PGRN) is a widely expressed pluripotent growth factor which plays a role in processes such as development, wound repair and inflammation by activating signaling cascades that control cell cycle progression and cell motility. Its function in the central nervous system is of interest, as mutations in the PGRN gene were found in cases of frontotemporal degeneration (FTLD). In addition, PGRN has also been linked to tumorigenesis. New cutting-edge publications have shown that progranulin might be a biomarker not only for FTLD, but also for other types of Alzheimers disease (AD). This new data even supposes the potential of progranulin to be a biomarker for MCI (Mild Cognitive Impairment), which would be a hallmark in AD research. Additionally, PGRN is described as a new ligand of TNF receptors and a potential therapeutic against inflammatory disease like arthritis. - Progranulin (PGRN) is a widely expressed pluripotent growth factor that plays a role in processes such as development, wound repair, and inflammation by activating signaling cascades that control cell cycle progression and cell motility. Its function in the central nervous system is of interest, as mutations in the PGRN gene were found in cases of frontotemporal degeneration (FTLD). In addition, PGRN has also been linked to tumorigenesis. New cutting-edge publications have shown that progranulin might be a biomarker not only for FTLD but also for other types of Alzheimers disease (AD). This new data even suppose the potential of progranulin to be a biomarker for MCI (Mild Cognitive Impairment), which would be a hallmark in AD research. Additionally, PGRN is described as a new ligand of TNF receptors and a potential therapeutic against inflammatory diseases like arthritis. Progranulin expression in plasma predicts GRN mutations status, independently of symptom onset proximity. Progranulin loss-of-function mutations are among the most frequent genetic causes, responsible for 20% of familial FTLD. If a patient carries a mutation in the progranulin gene, it can be detected using AdipoGens Progranulin (human) ELISA Kit. This is the only and unique kit on the market detecting all mutations of Progranulin [Reference 58].
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    41116158

References

  • Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration: R. Ghidoni, et al.; Neurology 71, 1235 (2008)
  • Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia: R. Rademakers, et al.; Hum. Mol. Genet. 17, 3631 (2008)
  • Serum progranulin concentrations may be associated with macrophage Infiltration into omental adipose tissue: B.S. Youn, et al.; Diabetes 58, 627 (2009)
  • Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members: N. Finch, et al.; Brain 132, 583 (2009)
  • Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease: M. Carecchio, et al.; J. Neurol. Sci. 287, 291 (2009)
  • Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes: M. De Riz, et al.; Neurosci. Lett. 469, 234 (2010)
  • Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study: E.C. Schofield, et al.; J. Alzheimers Dis. 22, 981 (2010)
  • A Novel Progranulin Mutation Causing Frontotemporal Lobar Degeneration with Heterogeneous Phenotypic Expression: G. Rossi, et al.; J. Alzheimers Dis. 23, 7 (2010)
  • Pathogenic cysteine mutations affect progranulin function and production of mature granulins: J. Wang, et al.; J. Neurochem. 112, 1305 (2010)
  • Microglial upregulation of progranulin as a marker of motor neuron degeneration: T. Philips, et al.; J. Neuropathol. Exp. Neurol. 69, 1191 (2010)